You are here

  • Home
  • Archive
  • Volume 29, Issue 7
  • Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Article metrics

Article menu
Download PDFPDF
Original Article
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

 

Online download statistics by month:

Online download statistics by month: August 2019 to April 2024

AbstractFullPdf
Aug 20192681613
Sep 201912692617
Oct 201918924
Nov 201914633
Dec 201913064
Jan 20208412
Feb 20209363
Mar 202011663
Apr 202012855
May 20207733
Jun 202015932
Jul 202012165
Aug 20209020
Sep 20209143
Oct 20209901
Nov 20207721
Dec 20208840
Jan 202111442
Feb 20217810
Mar 202122923
Apr 20217911
May 202169410
Jun 2021510
Jul 2021100
Aug 2021312
Sep 2021620
Oct 20216100
Nov 20215210
Dec 20215400
Jan 20227021
Feb 20229011
Mar 20228131
Apr 20227951
May 202211011
Jun 20228531
Jul 20225611
Aug 20229521
Sep 202212250
Oct 202210430
Nov 20228020
Dec 20227442
Jan 20236421
Feb 202312453
Mar 20238531
Apr 20233511
May 20237842
Jun 202312010
Jul 20235021
Aug 20237450
Sep 20235220
Oct 20239623
Nov 202316410
Dec 202316042
Jan 202410141
Feb 20249121
Mar 202410341
Apr 20247531
Total6494189115